InVivo Therapeutics Holdings Corp., a Cambridge company focused on drug-delivery technologies for spinal cord injuries, announced the appointment of Thomas R. Ulich, MD, as its chief scientific officer.
Ulich previously served as executive vice president of research and development of ConjuChem Biotechnologies from 2006 to 2010. Before that, he was senior vice president of R&D for Alnylam Pharmaceuticals, InVivo said in a press release.
In a statement InVivo chief executive Mark Perrin said, “Tom Ulich brings to InVivo a broad scientific background and expertise that will be invaluable as we build our biomaterials portfolio.”
InVivo was founded in 2005 with proprietary technology co-invented by Robert Langer, a professor at the Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital.